GlassScriptPhysician profile
Alexander Shekhter
NPI 1316924715
$2,412.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $436 · 2021: $236 · 2022: $40.85 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $743.81 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $303.12 | 2019-2020 | |
| Amarin Pharma, INC. | $275.51 | 2019-2021 | |
| Allergan, INC. | $261.95 | 2019-2020 | |
| Astellas Pharma US INC | $124.80 | 2019-2020 | |
| Radius Health, INC. | $100.92 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $89.80 | 2021-2022 | |
| Abbvie INC. | $75.50 | 2021 | |
| Scilex Pharmaceuticals INC. | $70.16 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $56.37 | 2019-2020 | |
| Horizon Therapeutics Plc | $52.52 | 2019-2020 | |
| Lilly USA, LLC | $45.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.79 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.00 | 2019 | |
| Amgen INC. | $37.93 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $37.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.00 | 2019 | |
| Endo Pharmaceuticals INC. | $17.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Shekhter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.